Join us at CVCF 2026 to explore how startups can scale and win in the age of AI.
Updated
October 29, 2026 11:39 PM
CVCF 2026 takes place on 4–5 November at Cyberport, Hong Kong. IMAGE: CYBERPORT
AI can help you build a startup, but it won’t automatically make you stand out. When everyone has access to similar tools, you need to give customers a reason to choose you and investors a reason to back you. So, how do you turn innovation into a competitive edge?
That question sits at the heart of Cyberport Venture & Capital Forum (CVCF) 2026, taking place on 4–5 November under the theme “Scaling in a Changing World: Winning the Next Competitive Cycle” and the message “Scale Up & Win.”
The two-day forum will feature more than 80 speakers discussing venture investment, AI-driven growth, emerging technologies and expansion into new markets. Day 1 will explore global investment trends and the next wave of innovation. Day 2 will feature CVCF 2026’s spotlight event, the Agentic Economy Summit, examining how agentic AI and digital assets could reshape business and finance. The wider programme will also include investor matching, founder pitches, 100+ Innovator Showcase, startup workshops and clinics.
With founders and investors navigating a fast-changing technology landscape, CVCF 2026 will explore what it takes to stay competitive, scale into new markets and turn emerging opportunities into business growth. Here’s a look at the key programmes lined up for this year’s forum.
Keynotes and Panels: Finding the Next Big Opportunity
Taara founder and CEO Mahesh Krishnaswamy will deliver the keynote The Innovation Playbook: Capitalizing on Moonshots and Faster Cycles in the Age of AI. The wider Day 1 programme will cover global investment trends, expansion into new markets, agentic AI and one-person companies.
For startups navigating the AI market, the panel Mastering the AI Bubble: Capital Rerouting and How Global Champions Stand Out will bring together panellists from Quona Capital, Alumni Ventures, FOV Ventures and Capital6 to discuss how investors assess startups and distinguish commercial potential from market hype. Other sessions will explore emerging technologies beyond AI software, including embodied AI, advanced computing and commercial aerospace.
Investor Matching and Networking: Connecting with Capital
Away from the conference sessions, MatchEasy will help founders and investors arrange one-to-one meetings, either onsite or online. Confirmed participants will receive access to the platform to explore potential matches and schedule meetings.
Investors can also discover local and international startups through the Founder Pitch programme, where entrepreneurs present their projects and ventures. Meanwhile, the Innovator Showcase offers a separate opportunity to explore emerging technology solutions through a virtual platform and selected on-site exhibits.
For founders seeking more tailored guidance, the Startup Clinics will offer one-to-one discussions with industry experts and experienced entrepreneurs on business challenges, fundraising and growth. Advance registration is required.
Hands-On Workshops: Strengthening Your Investment Pitch
Turning an innovative idea into a business that investors can back takes more than a strong pitch. CVCF 2026 will host practical workshops to help founders strengthen their fundraising strategies and make a stronger case to investors.
Led by Capital6 advisor Christine Keung, one workshop will explore how founders can align technical innovation with business goals, communicate their product’s value and prepare for fundraising. Another, led by Jeremy Dalton, advisor at FOV Ventures and SXSW Pitch, will help founders understand how investors assess startups, with opportunities to pitch live and receive direct feedback.
CVCF 2026’s spotlight event, the Agentic Economy Summit, will take place on 5 November under the theme “Intelligent Frontiers, Tokenised Horizons: Where Agentic AI Reshapes Business and Digital Assets Redefine How Value Moves.”
The summit will bring together technology and finance leaders to explore how agentic AI and digital assets could change the way businesses operate. Wolf Ruzicka, chief commercial officer at Unlimit, a global payments company, will discuss building and scaling agentic AI applications. Dr Feng Xiao, chairman and CEO of HashKey Group, will examine how digital identity, tokenised assets and money connect on-chain.
The discussions will also look at agent-led commerce, including how AI agents could help customers choose products and make purchases, and the payment systems needed to support these transactions. Other topics include Hong Kong dollar stablecoins and their potential role in payments and settlement, as well as the rise of one-person companies. The summit will also explore how founders can use AI agents to run their businesses with smaller teams, find customers and generate recurring revenue.
From AI-driven growth and cross-border investment to agentic AI and digital assets, CVCF 2026 brings together the people and ideas shaping the next phase of business. Whether you're preparing to raise capital, exploring new markets or assessing emerging technologies, the forum offers an opportunity to gain fresh perspectives and connect with investors, founders and industry leaders.
Exclusive for Ventureport readers: Use the promotional code cvcf26vp to access a Full Access Pass for HK$300, subject to confirmation of the offer by the organiser.
Date: 4–5 November 2026
Function Rooms, Level 3, Core E, Cyberport 3, Hong Kong
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.